Unravel Biosciences validates first Spanish Rett questionnaire

By AI, Created 9:42 AM UTC, May 20, 2026, /AGP/ – Unravel Biosciences announced the first Spanish-language adaptation and linguistic validation of the Rett Syndrome Behavioral Questionnaire, a step that could expand Rett syndrome research and clinical trial access across Spain and Latin America. The translated tool is already being used in Unravel’s Rett syndrome trial and is available for non-commercial use.

Why it matters: - The validated Spanish RSBQ gives clinicians, researchers, and drug developers a standardized caregiver tool for Rett syndrome in Spanish-speaking communities. - The translation could widen access to Rett syndrome clinical research across Spain and Latin America, where use of the measure had been limited by the lack of a validated Spanish version. - The tool is now available freely for non-commercial use by stakeholders in the Spanish-speaking Rett syndrome community.

What happened: - Unravel Biosciences announced the publication of the first Spanish-language adaptation and linguistic validation of the Rett Syndrome Behavioral Questionnaire. - The preprint is titled “Linguistic Validation of the Rett Syndrome Behavior Questionnaire Spanish Translation: a Two-Stage Caregiver Study Across Latin America.” - The study validated a translation of the RSBQ from British English while preserving linguistic equivalence. - Unravel researchers Melanie Polo Sanchez, Andrea Carolina Lesmes, Neal Muni, Frederic Vigneault, and Richard Novak conducted the study. - Unravel integrated the translated RSBQ into its clinical trial for RVL-001 in Rett syndrome, NCT07150013. - The company pointed readers to the preprint at the study preprint.

The details: - The RSBQ is a caregiver-reported outcome measure used in Rett syndrome research and clinical care. - Before this work, the RSBQ had only been validated in British English. - The translation was designed to keep the measure linguistically equivalent across Spanish-speaking settings. - The study surveyed 51 caregivers of Rett syndrome patients. - Participants came from Argentina, Mexico, Peru, Colombia, Uruguay, Guatemala, and the United States. - Unravel thanked the study participants and Rett syndrome foundations that supported the effort. - Neal Muni, Unravel’s chief medical officer, said the work addresses a critical gap in standardized behavioral assessment tools for Rett syndrome in non-English-speaking populations. - Muni also said diagnostic rates and recognition of Rett syndrome are increasing in Latin America, making accessible and culturally appropriate clinical instruments more urgent.

Between the lines: - The validation work supports broader trial inclusion by reducing one of the practical barriers to collecting consistent patient-reported data across languages. - Integrating the tool into an active clinical trial suggests Unravel sees the questionnaire as immediately useful, not just academically important. - The release also signals a push to build research infrastructure around Rett syndrome beyond English-speaking markets.

What’s next: - The Spanish RSBQ can now be used in non-commercial settings by the Spanish-speaking Rett syndrome community. - The validated questionnaire may support future Rett syndrome studies and caregiver assessments in Spain and Latin America. - Unravel says it is advancing multiple clinical trials in 2026 as part of its clinical-stage therapeutics platform.

The bottom line: - Unravel has turned a key Rett syndrome assessment tool into a Spanish-language resource, which could make research and trial participation more accessible across a much broader patient population.